For fluoxetine and paroxetine, dosage cutting is needed in case of coadministration with CYP2D6 substrates.
与治疗窗较窄的CYP2D 6底物合用时，应注意帕罗西汀和氟西汀的剂量调整。
Coadministration of hypothalamic PKC - inhibitor rottlerin with OAG prevented the ability of OAG to activate PKC - and lower glucose production.
下丘脑蛋白激酶C抑制剂卡马拉素和OAG同时给药会抑制OAG活化蛋白激酶c的能力并降低葡萄糖的生成。
Meanwhile, many drugs can influence the activity of CYP2D6 by competitive inhibition or induction, which is easy to cause interaction in coadministration.
而且CYP2D6能被多种药物竞争性抑制和诱导，药物联用时易产生相互作用。
应用推荐